CRISPR Therapeutics: An Uninspiring Start For Casgevy
CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Where Will Vertex Pharmaceuticals Be in 10 Years?
The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
NICE approval of Casgevy: a new era for sickle cell disease treatments in the UK
The sickle cell treatments available before Casgevy focused on symptom management such as reducing the frequency of vaso-occlusive crises (VOCs).
3 Magnificent Growth Stocks to Buy in March
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
MoneyWeek on MSN7d
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...
The Motley Fool3d
Where Will Vertex Pharmaceuticals Be in 10 Years?
The company's blood disorders treatment -- Casgevy -- also is a multibillion-dollar opportunity, according to Vertex. The drug launch unfolded last year, and since treatment involves a lengthy ...
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
Vertex Pharmaceuticals (NasdaqGS:VRTX) Gains UK Approval For New Cystic Fibrosis Treatment
Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...